Bristol-Myers Squibb sees highest patent filings and grants during August in Q3 2023
Bristol-Myers Squibb saw the highest growth of 156% in patent filings in August and 104% in grants in September in Q3 2023. Compared to Q2 2023, Q3 2023 saw an increase in patent filings by 56% and grants by 91%. GlobalData's DataBook provides a comprehensive analysis of Bristol-Myers Squibb's patent filings and grants. Buy the databook here. Bristol-Myers Squibb has been focused on protecting inventions in United States(US) with 100 publications in Q3 2023The United States(US) Patent Office dominates the patent filings and grants with nearly 28% filings and 16% grants. The United States(US), European Patent Office (E/P), China(CN), and World Intellectual Property Organization(WIPO) (WO) patent Office are among the top ten patent offices where Bristol-Myers Squibb is filings its patents. Among the top granted patent authorities, Bristol-Myers Squibb has 20% of its grants in European Patent Office (E/P), 16% in United States(US), and 11% in China(CN). Amgen could be the strongest competitor for Bristol-Myers SquibbIn terms of grant share, Bristol-Myers Squibb stands in one position among its competitors. Amgen and Johnson & Johnson secured the top positions according to recent patent publication data. Patents related to rare diseases and climate change lead Bristol-Myers Squibb's portfolioBristol-Myers Squibb has the highest number of patents in rare diseases followed by, climate change and cell & gene therapy. For rare diseases, nearly 45% of patents were filed and 70% of patents were granted in Q3 2023. Lung cancer related patents lead Bristol-Myers Squibb portfolio followed by lymphoma, and prostate cancerBristol-Myers Squibb has highest number of patents in lung cancer followed by lymphoma, prostate cancer, multiple myeloma (kahler disease) and melanoma. For lung cancer, nearly 2% of patents were filed and 2% of patents were granted in Q3 2023. For comprehensive analysis of Bristol-Myers Squibb's filings and grants, buy the databook here.
Access and buy GlobalData’s databook on the latest filings and grants activity for Bristol-Myers Squibb here.
What's Your Reaction?
